✦ LIBER ✦

Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C

✍ Scribed by Coffin, P. O.; Scott, J. D.; Golden, M. R.; Sullivan, S. D.

Book ID: 115449298
Publisher: University of Chicago Press
Year: 2012
Tongue: English
Weight: 647 KB
Volume: 54
Category: Article
ISSN: 1058-4838
DOI: 10.1093/cid/cis011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of population-based s

Cost-effectiveness of population-based screening for hepatitis C virus infection: has the time come?

✍ Thomas M. Shehab; John Inadomi; A.Mark Fendrick 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 25 KB

Cost-effectiveness of screening patients

Cost-effectiveness of screening patients for hepatitis C

✍ Fredric D. Gordon 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Cost effectiveness of screening immigran

Cost effectiveness of screening immigrants for hepatitis B

✍ William W. L. Wong; Gloria Woo; E. Jenny Heathcote; Murray Krahn 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB

Cost-effectiveness of screening blood do

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis

✍ C. Colin; P. Vergnon; A. M. Jullien; S. Excoffier; Y. Matillon; C. Trepo; J. P. 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 792 KB

Cost-Effectiveness of Preventing Hip Fra

Cost-Effectiveness of Preventing Hip Fracture in the General Female Population

✍ J. A. Kanis; A. Dawson; A. Oden; O. Johnell; C. de Laet; B. Jonsson 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 126 KB

Cost-effectiveness of hepatitis C virus

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

✍ Natasha K. Martin; Peter Vickerman; Alec Miners; Graham R. Foster; Sharon J. Hut 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB 👁 1 views

Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a 1 ribavirin) has been shown to be costeffective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment